| 000 | 01535 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250516202747.0 | ||
| 264 | 0 | _c20160115 | |
| 008 | 201601s 0 0 eng d | ||
| 022 | _a1879-114X | ||
| 024 | 7 |
_a10.1016/j.clinthera.2014.02.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKulpeng, Wantanee | |
| 245 | 0 | 0 |
_aCost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. _h[electronic resource] |
| 260 |
_bClinical therapeutics _cApr 2014 |
||
| 300 |
_a534-43 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aBudgets |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDasatinib _xeconomics |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImatinib Mesylate _xeconomics |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Chronic-Phase _xdrug therapy |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xeconomics |
| 650 | 0 | 4 |
_aPyrimidines _xeconomics |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aThailand |
| 700 | 1 | _aSompitak, Sumalai | |
| 700 | 1 | _aJootar, Saengsuree | |
| 700 | 1 | _aChansung, Kanchana | |
| 700 | 1 | _aTeerawattananon, Yot | |
| 773 | 0 |
_tClinical therapeutics _gvol. 36 _gno. 4 _gp. 534-43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clinthera.2014.02.008 _zAvailable from publisher's website |
| 999 |
_c23646699 _d23646699 |
||